Edwards Lifesciences (EW)
NYSEHealth CareMedical DevicesSnapshot 2026-07-07
$94.82-0.38%
Close 2026-07-07 · 1-day change
Reading EW? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track EW free→NYSEHealth CareMedical DevicesSnapshot 2026-07-07
Reading EW? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track EW free→QuarterlyIQ Insights · EW
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 13 valuation methods, at three horizons. Current price $94.82. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $95 EW trades at 35× p/e, below its 37× p/e peer median, but our blended $81 fair value sits below the price. We hold it with medium confidence: our number sits below the analyst range. Analysts target $85–$110. Note: our $81 fair value sits below the entire analyst range ($85–$110). Even valued only for durable growth at sustainable margins, it's worth about $106 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
$85.00 – $110.00 (median $97.50) · 8 analysts · as of 2026-07-06
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 67% over what the business is worth with no growth; closing that gap needs roughly 7.0 years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $2.74/sh owner earnings.
Roughly priced in line with peers.
Around its own typical valuation.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $97.50 | — | — | Analyst | high |
| dcf fcfe | 12M | $40.33 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $43.72 | — | — | Hist. CAGR | high |
| graham number | 12M | $32.87 | — | — | TTM | high |
| Mgmt guidance | 12M | $108.65 | 36.5 | 2.98 | Mgmt | high |
| Peer EV/EBITDA | 12M | $21.68 | 6.2 | 3.01 | TTM | high |
| Peer P/FCF | 12M | $44.95 | 24.0 | 1.88 | TTM | high |
| Peer P/E | 12M | $103.26 | 36.5 | 2.83 | TTM | high |
| Peer P/S | 12M | $30.15 | 2.8 | 10.86 | TTM | high |
| PEG | 12M | $96.59 | 34.2 | 2.83 | TTM | high |
| residual income | 12M | $23.31 | — | — | TTM | high |
| Own P/E history | 12M | $91.62 | 32.4 | 2.83 | TTM | high |
| triangulated | 12M | $102.38 | 36.5 | 2.80 | Triangulated | high |
| Mgmt guidance | 3Y | $169.93 | 36.5 | 4.65 | Mgmt(prov.) | medium |
| Peer P/FCF | 3Y | $49.70 | 24.0 | 2.07 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $109.28 | 36.5 | 2.99 | Analyst | medium |
| Peer P/S | 3Y | $31.49 | 2.8 | 11.34 | guidance | medium |
| PEG | 3Y | $102.22 | 34.2 | 2.99 | Analyst | medium |
| Own P/E history | 3Y | $96.96 | 32.4 | 2.99 | Analyst | medium |
| Mgmt guidance | 5Y | $228.96 | 36.5 | 6.27 | Mgmt(prov.) | high |
| Peer P/FCF | 5Y | $53.14 | 24.0 | 2.22 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $94.12 | 36.5 | 2.58 | Analyst | high |
| Peer P/S | 5Y | $27.12 | 2.8 | 9.77 | guidance | high |
| PEG | 5Y | $88.04 | 34.2 | 2.58 | Analyst | high |
| Own P/E history | 5Y | $83.51 | 32.4 | 2.58 | Analyst | high |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.